{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:14Z","timestamp":1707525074023},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,20]]},"DOI":"10.7759\/cureus.36392","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T10:43:41Z","timestamp":1679309021000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Muhammad Talha","family":"Haseeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Nouman Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FNU","family":"Avanteeka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar Abdul Rehman","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewan","family":"Zubaer Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithum","family":"Senaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bsher","family":"Almaalouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsha","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(97)00343-4","article-title":"Where are all the women with heart failure?","volume":"30","author":"Lindenfeld J","year":"1997","unstructured":"Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure?. J Am Coll Cardiol. 1997, 30:1417-9. 10.1016\/s0735-1097(97)00343-4","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"Heart disease and stroke statistics--2013 update: a report from the American Heart Association","volume":"127","author":"Go AS","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL, et al.. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013, 127:e6-e245. 10.1161\/CIR.0b013e31828124ad","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow GC","year":"2007","unstructured":"Fonarow GC, Stough WG, Abraham WT, et al.. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007, 50:768-77. 10.1016\/j.jacc.2007.04.064","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.08.016","article-title":"Healthy lifestyles and personal responsibility","volume":"64","author":"Heidenreich PA","year":"2014","unstructured":"Heidenreich PA. Healthy lifestyles and personal responsibility. J Am Coll Cardiol. 2014, 64:1786-8. 10.1016\/j.jacc.2014.08.016","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart Disease and Stroke Statistics-2021 Update: a report from the American Heart Association","volume":"143","author":"Virani SS","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al.. Heart Disease and Stroke Statistics-2021 Update: a report from the American Heart Association. Circulation. 2021, 143:e254-743. 10.1161\/CIR.0000000000000950","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy CW","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017, 136:e137-61. 10.1161\/CIR.0000000000000509","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter R","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, et al.. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019, 21:998-1007. 10.1002\/ejhf.1498","journal-title":"Eur J Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"74","author":"Hollenberg SM","year":"2019","unstructured":"Hollenberg SM, Warner Stevenson L, Ahmad T, et al.. ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019, 74:1966-2011. 10.1016\/j.jacc.2019.08.001","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction\u3000- results from the PARALLEL-HF study","volume":"85","author":"Tsutsui H","year":"2021","unstructured":"Tsutsui H, Momomura SI, Saito Y, et al.. Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction\u3000- results from the PARALLEL-HF study. Circ J. 2021, 85:584-94. 10.1253\/circj.CJ-20-0854","journal-title":"Circ J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli MF","year":"2021","unstructured":"Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2021, 23:127-35. 10.1002\/ejhf.2076","journal-title":"Eur J Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab849.055","article-title":"Impact of angiotensin-receptor neprilysin inhibitor on reverse cardiac remodeling in patients with heart failure with reduced ejection fraction (hfref)","volume":"43","author":"Atan N","year":"2022","unstructured":"Atan N, Loch AL, Hadi FI. Impact of angiotensin-receptor neprilysin inhibitor on reverse cardiac remodeling in patients with heart failure with reduced ejection fraction (hfref). Eur Heart J. 2022, 43:849-55. 10.1093\/eurheartj\/ehab849.055","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022889","article-title":"Angiotensin receptor neprilysin inhibition and associated outcomes by race and ethnicity in patients with heart failure with reduced ejection fraction: data from CHAMP-HF","volume":"11","author":"Chapman B","year":"2022","unstructured":"Chapman B, Hellkamp AS, Thomas LE, et al.. Angiotensin receptor neprilysin inhibition and associated outcomes by race and ethnicity in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. J Am Heart Assoc. 2022, 11:e022889. 10.1161\/JAHA.121.022889","journal-title":"J Am Heart Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai AS","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, et al.. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019, 322:1077-84. 10.1001\/jama.2019.12843","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4236\/ojim.2020.101003","article-title":"Effect of angiotensin receptor-neprilysin inhibitor versus valsartan on cardiac status in patients with chronic heart failure with reduced ejection fraction: a randomized clinical trial in Rangpur Medical College Hospital, Bangladesh","volume":"18","author":"Ghafur S","year":"2020","unstructured":"Ghafur S, Zahid MA, Sarkar H, Barman RN, Al-Mahmud A, Rahman M, Islam H. Effect of angiotensin receptor-neprilysin inhibitor versus valsartan on cardiac status in patients with chronic heart failure with reduced ejection fraction: a randomized clinical trial in Rangpur Medical College Hospital, Bangladesh. Open J Int Med. 2020, 18:21. 10.4236\/ojim.2020.101003","journal-title":"Open J Int Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.794707","article-title":"Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study","volume":"9","author":"Hsiao FC","year":"2022","unstructured":"Hsiao FC, Lin CP, Yu CC, Tung YC, Chu PH. Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study. Front Cardiovasc Med. 2022, 9:794707. 10.3389\/fcvm.2022.794707","journal-title":"Front Cardiovasc Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang DH","year":"2019","unstructured":"Kang DH, Park SJ, Shin SH, et al.. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019, 139:1354-65. 10.1161\/CIRCULATIONAHA.118.037077","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001294","article-title":"Beneficial and harmful effects of sacubitril\/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"7","author":"Nielsen EE","year":"2020","unstructured":"Nielsen EE, Feinberg JB, Bu FL, Hecht Olsen M, Raymond I, Steensgaard-Hansen F, Jakobsen JC. Beneficial and harmful effects of sacubitril\/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart. 2020, 7:10.1136\/openhrt-2020-001294","journal-title":"Open Heart"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow GC","year":"2016","unstructured":"Fonarow GC, Hernandez AF, Solomon SD, Yancy CW. Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol. 2016, 1:714-7. 10.1001\/jamacardio.2016.1724","journal-title":"JAMA Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt B","year":"2023","unstructured":"Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions. JACC Basic Transl Sci. 2023, 8:88-105. 10.1016\/j.jacbts.2022.05.010","journal-title":"JACC Basic Transl Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego C","year":"2018","unstructured":"de Diego C, Gonz\u00e1lez-Torres L, N\u00fa\u00f1ez JM, et al.. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018, 15:395-402. 10.1016\/j.hrthm.2017.11.012","journal-title":"Heart Rhythm"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America Guideline for the management of heart failure: executive summary","volume":"28","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America Guideline for the management of heart failure: executive summary. J Card Fail. 2022, 28:810-30. 10.1016\/j.cardfail.2022.02.009","journal-title":"J Card Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v6.i1.4","article-title":"Physiology of natriuretic peptides: the volume overload hypothesis revisited","volume":"6","author":"Arjamaa O","year":"2014","unstructured":"Arjamaa O. Physiology of natriuretic peptides: the volume overload hypothesis revisited. World J Cardiol. 2014, 6:4-7. 10.4330\/wjc.v6.i1.4","journal-title":"World J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer MA","year":"2021","unstructured":"Pfeffer MA, Claggett B, Lewis EF, et al.. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021, 385:1845-55. 10.1056\/NEJMoa2104508","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319545","article-title":"Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure","volume":"107","author":"Griffin J","year":"2021","unstructured":"Griffin J, Cheng R. Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure. Heart. 2021, 107:1364-6. 10.1136\/heartjnl-2021-319545","journal-title":"Heart"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/143910-comparison-of-efficacy-and-safety-of-angiotensin-receptor-neprilysin-inhibitors-in-patients-with-heart-failure-with-reduced-ejection-fraction-a-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:48Z","timestamp":1707508668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/143910-comparison-of-efficacy-and-safety-of-angiotensin-receptor-neprilysin-inhibitors-in-patients-with-heart-failure-with-reduced-ejection-fraction-a-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.36392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,20]]}}}